Rhythm Pharmaceuticals CEO David Meeker Sells $5.13M in Stock

Rhythm Pharmaceuticals President and CEO David P. Meeker sold 50,000 shares of company stock on September 14, 2026, for a total value of approximately $5.13 million. The sale was conducted under a pre-arranged trading plan, and it coincided with the exercise of long-held employee stock options.

Concurrent with the sale, Meeker acquired 50,000 shares by exercising employee stock options at a strike price of $6.05 per share. These options were granted to him on February 8, 2017, as part of the firm's compensation structure.

Execution Under Rule 10b5-1

The transaction was executed pursuant to a Rule 10b5-1 trading plan that Meeker adopted on June 15, 2026. Corporate executives use this regulatory mechanism to manage their equity holdings while remaining compliant with securities laws.

According to SEC guidelines, a Rule 10b5-1 plan allows company insiders to establish a predetermined schedule for buying or selling stocks. By setting these parameters in advance, executives execute trades at future dates regardless of their possession of material, non-public information at the time of the transaction. This structure provides an affirmative defense against potential allegations of insider trading.

Insider Equity Management

Investors monitoring corporate governance view the use of a 10b5-1 plan as a standard practice for liquidating or rebalancing equity compensation. Because the plan was established in June, the September sale was automated. This removed the discretion of the CEO to time the market based on internal company developments occurring closer to the date of the sale.

Rhythm Pharmaceuticals develops therapies for rare genetic diseases of obesity and uses equity-based compensation as a component of its executive retention strategy. The exercise of options granted nearly a decade ago reflects the maturation of equity awards issued during the company's earlier growth phases.